MRK News 60.36 09/25/2014 05:21:39 Merck & Company (MRK)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merck & Company (MRK) 60.36 $MRK

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
M2 - 3 mins ago
Research and Markets (http://www.researchandmarkets.com/research/fsgrrm/pharmapoint) has announced the addition of the "PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. HCV Market is Expected to Grow During the Forecast Period The HCV market generated approximately $4.2 billion from global sales in 2012. Over the next 10 years, this market is expected to grow to reach $12.8 billion, with major growth occurring in the main HCV markets, such the US. Pharma Giants Battle as New Entrants Leverage Interferon-Sparing and Interferon-Free HCV Regimens to Capture Market Share Companies Prioritize the Development of All-Oral HCV Regimens The current HCV therapies have satisfactory efficacy, but they still require co-administration with peginterferon and ribavirin for the majority of patients. The shortcomings of the first-generation DAAs (Incivek and Victrelis [boceprevir]) and the first-to-market interferon-sparing (Sovaldi and Olysio) regimens have created an opportunity for the next-generation interferon-free therapies, especially in the US, Japan, and many European countries. The authors anticipates that more tolerable and convenient all-oral therapies will experience robust uptake in these markets. All of the pipeline agents covered in this report are more tolerable and require shorter durations of therapy compared with Incivek/Victrelis triple therapy, but interferon-free regimens, including Gilead's Sovaldi/ledipasvir, Merck's combination therapy (MK-5172/MK-8741), AbbVie's combination therapy (ABT-450/ombitasvir dasabuvir)), and BMS' combination therapy (daclatasvir/asunaprevir/BMS-791325) are expected to best address key unmet needs. Some of the main drivers of market growth are expected to be: - Introduction of interferon-free HCV regimens, which have an improved side effect profile compared with the first-generation direct-acting antiviral (DAA) and interferon-sparing HCV therapies - The arrival of fixed-dose combination therapies, which are expected to help simplify treatment - Increase in patient awareness of HCV through screening initiatives and public awareness campaigns - A paradigm shift toward the preventative treatment of HCV in most countries The barriers limiting the growth of the market include: - Limited patient awareness regarding the threat of HCV - Concerns over decreasing healthcare spending as part of government austerity measures Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Merck - Roche - Vertex - Janssen - Gilead - AbbVie - Bristol-Myers Squibb - Boehringer Ingelheim - Achillion - Scynexis - Idenix - Presidio - Novartis For more information visit http://www.researchandmarkets.com/research/fs...harmapoint

Acute Coronary Syndrome - Current and Future Players: Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GSK, Janssen Pharma, Merck, Pfizer & Sanofi
M2 - 51 mins ago
Research and Markets (http://www.researchandmarkets.com/research/lx7n7r/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Current and Future Players" report to their offering. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing ACS Market. The report identifies and analyses the key companies shaping and driving the global ACS market. The report provides insight into the competitive ACS landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for ACS - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of ACS sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving ACS market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global ACS market landscape? Identify, understand and capitalize Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook 4 Current and Future Players 5 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/lx...harmapoint

Merck to Hold Third-Quarter 2014 Sales and Earnings Conference Call on October 27
Business Wire - Wed Sep 24, 4:00PM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2014 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Monday, Oct. 27. During the call, company executives will provide an overview of Merck's performance for the quarter.

Research and Markets: PharmaPoint: Asthma - Current and Future Players Report: GSK, Merck & Co, AstraZeneca/MedImmune, Novartis, Roche/Genentech, Teva & Boehringer Ingelheim
Business Wire - Wed Sep 24, 12:43PM CDT
Research and Markets (http://www.researchandmarkets.com/research/gx97bp/pharmapoint) has announced the addition of the "PharmaPoint: Asthma - Current and Future Players" report to their offering.

PharmaPoint: Asthma - Current and Future Players Report: GSK, Merck & Co, AstraZeneca/MedImmune, Novartis, Roche/Genentech, Teva & Boehringer Ingelheim
M2 - Wed Sep 24, 11:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2njp2k/pharmapoint) has announced the addition of the "PharmaPoint: Asthma - Current and Future Players" report to their offering. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Asthma Market. The report identifies and analyses the key companies shaping and driving the global Asthma market. The report provides insight into the competitive Asthma landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Asthma - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Asthma sector through market impact analysis, future market scenario and company analysis Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook 3.1 Global Markets 3.1.1 Forecast 3.1.2 Drivers and Barriers - Global Issues 4 Current and Future Players 4.1 Overview 4.2 Trends in Corporate Strategy 4.3 Company Profiles 4.3.1 GlaxoSmithKline 4.3.2 Merck & Co. 4.3.3 AstraZeneca/MedImmune 4.3.4 Novartis 4.3.5 Roche/Genentech 4.3.6 Teva 4.3.7 Boehringer Ingelheim 5 Appendix For more information visit http://www.researchandmarkets.com/research/2n...harmapoint

WiserTogether Raises $9 Million in Series B Led by Martin Ventures and Merck Global Health Innovation Fund
PR Newswire - Wed Sep 24, 6:31AM CDT
WiserTogether, Inc., the healthcare treatment comparison software company, today announced the completion of its Series B funding of $9 million led by Martin Ventures and Merck Global Health Innovation Fund (Merck GHI). The company's founder and CEO, Shub Debgupta, as well as all prior institutional investors, including Grotech Ventures, Harbert Venture Partners, 7Wire Ventures and Blue Heron Capital participated in the round.

Medical Diagnostic Devices Research Digest - H1 2014: Latest News for Medical Devices, In-Vitro Diagnostic Devices & Medical Imaging Devices
M2 - Wed Sep 24, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rnbznw/medical) has announced the addition of the "Medical Diagnostic Devices Research Digest - H1 2014" subscription to their offering. The Medical Diagnostic Devices Research Digest is a round-up of all the most important research in the industry each quarter available as an annual subscription, gathered from over 50 sources including associations, market intelligence companies, Journals, company news articles , consultants and industry participants. Updated quarterly, the Digest allows you to: - Quickly update yourself on the latest research findings, gathered and organised for you. - Get our Expert Analysts' perspectives on the latest research. - Link through to the original research to review or purchase. Key Topics Covered: 1 Global Medical Devices Research - Medical Devices M&A Value Falls by Over Half in 2013 Against 2012 - Global Medical Devices Market Showing Only Moderate Growth - Big Fall In Regulatory Approvals of Medical Devices - Top 10 Medical Device Companies 2013 - Cyber-Attacks on Medical Devices Endanger Patients' Lives - US Medical Device Manufacturers Paid $1bn in Excise Tax In 2013 - Strategic Rationale of Medtronic-Covidien Deal - Manufacturing Costs Of Medical Devices Significantly Lower Outside The U.S. - New Trends in Private Healthcare Service Providers in APAC, But Hospitals Remain the Major Providers - China's Healthcare Reform Continues to Drive Its Medical Devices Market 2 In Vitro Diagnostic Devices Research - Global In Vitro Diagnostic (IVD) Devices Market Moderate Growth - Johnson & Johnson Divests Its IVD Business - Becton Dickinson Leads Global Flow Cytometry Market - Clinical Chemistry And Coagulation Tests Dominate North America IVD Market - Cost Of Cholesterol Tests Vary Widely Across The U.S. - Molecular Diagnostics' Rapid Growth In The U.S. IVD Market - U.S. Companion Diagnostics Significant Growth - Hospital-Acquired Infections (HAI) Drive The U.S. Infectious Diseases Testing Market - U.S. IVD Market, Competitive Landscape 2013 - New Entrants Gain Share In The U.S. Blood Testing Market - European Companion Diagnostics' Remarkable Growth - European Law Restricts German IVD Market Growth - French IVD Market Restraints - French Government Strengthens Transparency In Healthcare Sector - Public Healthcare Budget Impacts On Italian IVD Market - Spanish IVD Market Declines Substantially - Nail Test For Bone Quality Launched In The UK - Taxes In Brazil Suppress IVD Market Growth - Brazilian IVD Manufacturers Gain Momentum - Rapid Growth Forecast For Chinese Digital Pathology Market - Public-Private Partnerships Drives Indian IVD Market - Indian IVD Market - Competitive Landscape - Indian Clinical Laboratories Still Use Manual Methods 3 Medical Imaging Devices Research - Diagnostic Ultrasound Market In Developed Economies Depends On Replacement Of Already Installed Systems - Film-Screen Mammography (FSM) Systems Usage Phased Out In Europe - Adoption Of Breast Tomosynthesis System Faster In Europe Than The U.S. - Prices Of CT And MRI Scan Vary Widely Across The U.S. - Medical Imaging Contribution To Washington State's Economy - Mammography Reduces U.S. Mortality Rate - Canadian Initiative Controls Overutilization Of Lumbar MRI Scans - China's Diagnostic X-Ray Imaging Market Sees Rapid Growth Companies Mentioned - Abbott - Abbott Laboratories - Agappe Diagnostics - Arkray - Beckman Coulter Inc. and Becton Dickinson - Bio-Rad and Danaher - CPC Diagnostics - Crescent Diagnostics - DASA Diagnostic Laboratory Group - EMD Millipore - GrupoFleury and Hermes Pardini - Hologic - Hologic - iCyt Sysmex - Johnson and Johnson - LabCorp - Lilac Medicare - Merck - Mindray - Ortho-Clinical Diagnostics - Partec - Qiagen - Quest Diagnostics - Roche Diagnostics - Siemens Healthcare - Sony Technology - Theranosis - Thermo fisher and Alere - Transasia Bio-Medicals - Tulip and Bhat-Biotech For more information visit http://www.researchandmarkets.com/research/rnbznw/medical

Global Eczema Therapeutics Pipeline Review 2014 - 5 Companies & 6 Drug Profiles
M2 - Wed Sep 24, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5txcp4/eczema_pipeline) has announced the addition of the "Eczema - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Eczema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eczema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Merck & Co., Inc. - FAES Farma SA - China Biologic Products, Inc. - GlycaNova Norway AS - Immune Response BioPharma, Inc. Drug Profiles - bilastine - desloratadine - Drug for Atopic Dermatitis and Eczema - Varicella Hyperimmune Globulins - IR-444 - MM-1501 For more information visit http://www.researchandmarkets.com/research/5t...a_pipeline

Evacetrapib Report 2014 - Forecast and Market Analysis to 2023
M2 - Wed Sep 24, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6z85cw/evacetrapib) has announced the addition of the "Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" report to their offering. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially. In addition to Merck's anacetrapib, Eli Lilly will be vying for space in the cholesterol market with its own Phase III CETP inhibitor, evacetrapib. Like the researchers at Merck, the CETP inhibitor team at Eli Lilly believes they have learned from the torcetrapib and dalcetrapib clinical trial failures. As with any aspirational LDL-C treatment, Eli Lilly had to demonstrate the LDL-C lowering capacity of evacetrapib. Scope - Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Aricept for the top seven countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Unmet Need and Opportunity - Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques - Therapies that Treat Fibrotic Myocardium and Associated Comorbidities - LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients - Antidotes for New Oral Anticoagulants (NOACs) - Blood-Thinning Agents with Significantly Reduced Bleeding Risks 7 Pipeline Assessment 8 Evacetrapib 9 Appendix For more information visit http://www.researchandmarkets.com/research/6z...vacetrapib

Robbins Arroyo LLP: Acquisition of Sigma-Aldrich Corporation (SIAL) by Merck KGaA (MRK) May Not Be in Shareholders' Best Interests
GlobeNewswire - Tue Sep 23, 5:35PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Sigma-Aldrich Corporation by Merck KGaA. On September 22, 2014, the companies announced that Sigma-Aldrich and Merck signed a definitive merger agreement pursuant to which Merck will acquire all outstanding shares of Sigma-Aldrich for $140.00 per share in cash.

INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board of Directors of Sigma-Aldrich Corporation Regarding the Fairness of the Sale of the Company to Merck
Business Wire - Tue Sep 23, 11:14AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Sigma-Aldrich Corporation (NasdaqGS: SIAL) ("Sigma-Aldrich" in connection with the sale of the Company to Merck.

Herpes Zoster (Shingles) Therapeutics Pipeline Review 2014 - 7 Companies & 9 Drug Profiles
M2 - Tue Sep 23, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7qstv6/herpes_zoster) has announced the addition of the "Herpes Zoster (Shingles) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Merck & Co., Inc. - Astellas Pharma Inc. - Foamix Ltd. - Arcion Therapeutics, Inc. - Epiphany Biosciences, Inc. - NAL Pharmaceuticals Ltd. Drug Profiles - amenamevir - GSK-1437173A - V-212 - FV-100 - valomaciclovir stearate - lidocaine - acyclovir - NAL-3221 - NAL-3223 For more information visit http://www.researchandmarkets.com/research/7q...pes_zoster

Stock Market News for September 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 9:10AM CDT
Growth worries in China and disappointing home sales data dragged down the benchmarks on Monday

Biopharmaceutical and Vaccine Production Markets to 2018
M2 - Tue Sep 23, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h2pzn6/biopharmaceutical) has announced the addition of the "Biopharmaceutical and Vaccine Production Markets" report to their offering. Though biotechnology has created many new therapies and vaccines - including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders - there are still huge challenges during the final stages of clinical drug testing for new biopharmaceuticals, as manufacturers decide when and how to risk production capital to upscale while anticipating FDA or EMA approval. During the past five years, estimates for biopharmaceuticals have varied widely as analysts and producers have juggled the promise of new drugs with the technological and financial risks of manufacturing them efficiently. Biopharmaceutical and Vaccine Production Markets examines the total biopharmaceutical manufacturing market, including in its estimates all costs related to biopharmaceutical and vaccine production. It includes the following useful information for business planning: - Market Forecasts and Estimates of Biopharmaceutical Manufacturing Costs - Vaccine Production Estimates - Trend Discussion - Production Methods - The Competitive Environment, including Contract Manufacturing and Outsourcing - Regulation of the Market - Company Profiles The report contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing markets, with forecasts to 2018. The current competitive environment is noted, listing selected biopharmaceutical contract manufacturers, selected top-selling biopharmaceuticals, selected Asian biomanufacturing contract manufacturing organizations (CMOs), the top 10 biopharma companies based on 2012 biopharma revenues, and the top manufacturers by global biopharmaceutical manufacturing capacity. Report profiles of major contract manufacturers: - Lonza AG - Boehringer Ingelheim GmbH - FUJIFILM Diosynth Biotechnologies - Sandoz - Royal DSM - Rentschler Biotechnologie - Celonic - BIOMEVA GmbH - ProBioGen AG - Baxter BioPharma Solutions/Baxter Bioscience Major biologics firms : - Amgen - Genentech/Roche - AbbVie Inc. (Abbott) - Biogen Idec - Regeneron Pharmaceuticals - Alexion Pharmaceuticals - Crucell /Johnson & Johnson - GlaxoSmithKline - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur Other contract manufacturers profiled - AAIPharma - A-Bio Pharma Pte Ltd. - ABL, Inc. - Affinity Life Sciences, Inc. - Ajinomoto Aminoscience, LLC - Alliance Medical Products, Inc. - Alpha Biologics - Biotecnol - Boston Mountain Biotech - Glycobia - Sutro Biopharma Key Topics Covered: - Executive Summary - Commercial Production - Forecasts - Regulation - Competitive Environment - Patents - Geography - Profiles For more information visit http://www.researchandmarkets.com/research/h2...maceutical

Regulatory Approval, Presentation of Data, Appointment, Clinical Study Results, and Increase in Quarterly Dividend - Research Reports on Johnson & Johnson, Merck, Medtronic, Amgen and Covidien
PR Newswire - Tue Sep 23, 8:05AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Medtronic, Inc. (NYSE: MDT), Amgen Inc. (NASDAQ: AMGN) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6679-100free.

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sigma-Aldrich Corporation. Concerning its Proposed Sale to Merck --SIAL
PR Newswire - Tue Sep 23, 8:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against the Board of Directors of Sigma-Aldrich Corporation. ("Concur Technologies" or the "Company" (NasdaqGS: SIAL) related to the proposed acquisition of the Company by SAP America, Inc., a subsidiary of SAP SE. The transaction is valued at around $17 billion or $140.00 per share.

Ophthotech Corporation Names Michael G. Atieh as Executive Vice President and Chief Financial and Business Officer
Business Wire - Tue Sep 23, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that Michael G. Atieh has been named Executive Vice President, Chief Financial and Business Officer and Treasurer effective September 30, 2014. Mr. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the Company of his intention to retire effective September 30, 2014.

Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
PR Newswire - Tue Sep 23, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has appointed Rasappa Arumugham, PhD, as its Vice President of Biopharmaceutical Development. Dr. Arumugham has over 25 years of diverse experience in biopharmaceutical research and development (R&D) in the areas of formulation research, analytical method development, quality control (QC), and manufacturing. He has a proven track record in development, scale-up, and technology transfer supporting commercialization of vaccines and biologics, including Prevnar®, TetramuneTM, HibTITER®, Meningitec® Conjugate and meningitis B (bivalent rLP2086) Lipoprotein Subunit Vaccines.

Research and Markets: Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry
Business Wire - Tue Sep 23, 3:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b9xlc3/global) has announced the addition of the "Global Pneumococcal Vaccines Market 2014-2018" report to their offering.

Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry
M2 - Tue Sep 23, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2276th/global) has announced the addition of the "Global Pneumococcal Vaccines Market 2014-2018" report to their offering. The Global Pneumococcal Vaccines market to grow at a CAGR of 4.9% over the period 2013-2018 Pneumococcus (Streptococcus pneumonia), a pathogenic bacterium, is the leading cause of serious illness across the globe. It is the main cause of pneumonia, sinusitis, blood infections, meningitis, and middle ear infections (otitis media). Pneumococcal disease affects children and the elderly, and it is one of the leading infectious diseases worldwide. It kills almost 1.6 million people (including more than 800,000 children under the age five years) every year. Pneumococcal disease can be prevented by vaccination. Vaccination involves the introduction of dead or weakened antigen into the human body, which in turn produces lymphocytes to counter the infection and any future invasions by that antigen. One of the emerging trends in this market is strategic alliances of vendors in the market, resulting in consolidation. Such alliances are intended to increase the market penetration of the acquirer or to enhance the product portfolio of the parent company. According to the report, the major driving force in the market is the inclusion of the pneumococcal vaccination in the national immunization schedule of many countries, which helps to increase the consumption of vaccines in the market, thereby boosting growth. Further, the report states that the inadequate vaccine coverage in the world is a major challenge to the market growth, resulting in low reach of the vaccines in the market, which restrains growth. Key Vendors - GlaxoSmithKline - Merck - Pfizer Other Prominent Vendors - Lupin - Sanofi Pasteur MSD - S K Chemicals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Type - Market Assessment of Top Pneumococcal Vaccines - Geographical Segmentation - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/2276th/global
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 18

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Subsplash Builds a Broader Church Software Stack in 2026

Updated Category News Views 54

Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 39

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 11

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 28

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 71

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 84

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
COP31 Puts China’s Weather-to-Energy Model on View

Updated Category News Views 55

Storm maps are becoming operating manuals, and that is the hard reality behind a November 13 COP31 event in Antalya, Türkiye. The session, “From Early Warning to Energy Action: Pathways for Global Climate Diplomacy and Cooperation,” put China’s effort to tie meteorological intelligence to energy-system decisions under an international spotlight. This is not...

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 116

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
SoCalGas Data Program Puts Metering Case Into Focus

Updated Category News Views 43

Buried beneath the usual utility-company polish is a pretty sensible idea: find waste before a customer gets walloped by a bill. SoCalGas says its Advanced Meter Analytics program has helped customers avoid an estimated $11 million in unnecessary natural-gas costs since 2019. That is not a number likely to move Sempra’s earnings by itself, and nobody should pretend...

Continue Reading

Top 5 Most Recently Viewed Articles

Lifeboat Market Growth Drivers & Future Projections 2024-2033

Updated Category News Views 82

Lifeboat Market Growth Drivers & Future Projections Recent market analysis indicates that the global lifeboat market is on a trajectory of significant growth, expected to expand from a valuation of $311.0 million in 2023 to approximately $416.3 million by 2033, at a compound annual growth rate (CAGR) of 3.2%. This upward trend is primarily driven by stringent maritime...

Continue Reading
Envista Holdings Corp: An Insight Into Market Trends

Updated Category News Views 198

Understanding Envista Holdings Corp's Market Dynamics Envista Holdings Corp (NYSE: NVST) has witnessed notable movements in its short interest percentage recently. The figure has seen a decline of 11.19% from the last available report, indicating a shift in market sentiment. Currently, there are approximately 9.10 million shares sold short, representing 6.67% of the...

Continue Reading
Breakthrough Medical Device Addresses Lipohypertrophy in Diabetes

Updated Category News Views 544

Revolutionizing Diabetes Treatment with Embrace Patch Recent clinical trials have shed light on the embrace Active Site Care compression patch, a pioneering medical device that has demonstrated its efficacy in treating lipohypertrophy (LH) in individuals using insulin for diabetes management. This breakthrough reveals how comprehensive care and innovative technology can...

Continue Reading
Investors' Perspectives on Carpenter Technology Corp's Stock Trends

Updated Category News Views 184

Understanding Carpenter Technology Corp's Short Interest Carpenter Technology Corp (NYSE: CRS) has seen a significant shift in its short interest as a percentage of float, which has decreased by 18.6% since its last report. According to the latest data from exchanges, the current short interest stands at approximately 2.54 million shares sold short, equating to around...

Continue Reading
Exploring Palantir's Future: Sustainable Growth or a Bubble?

Updated Category News Views 416

Palantir Technologies Inc: A Deep Dive into Its Future Palantir Technologies Inc (NASDAQ: PLTR) is attracting considerable attention from investors and industry watchers alike. Renowned for its cutting-edge AI-driven software solutions, Palantir is at the forefront of transforming both defense and enterprise sectors. Following a remarkable surge of 400% in stock value...

Continue Reading